MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income (loss)
$205,991K
Proceeds from exercise of
stock options and...
$13,157K
Proceeds from
liabilities related to the...
$6,000K
Stock-based compensation
expense
$70,154K
Non-cash interest
expense on liabilities...
$66,236K
Depreciation and
amortization
$13,553K
Deferred income taxes
$9,310K
Other
$2,994K
Net cash provided by
(used in) operating...
$70,504K
Net cash provided by
financing activities
$15,714K
Canceled cashflow
$297,734K
Canceled cashflow
$3,443K
Net increase in
cash, cash...
$53,612K
Canceled cashflow
$32,606K
Accounts payable,
accrued expenses and...
-$176,033K
Accounts receivable, net
$110,421K
Prepaid expenses and
other assets
$6,323K
Inventory
$3,324K
Deferred revenue
-$1,633K
Sales and maturities
of marketable...
$213,191K
Proceeds from maturity of
restricted and other...
$48,825K
Repayment of liabilities
related to the sale of...
$3,434K
Other financing
activities
-$9K
Net cash (used in)
provided by investing...
-$25,542K
Effect of exchange rate
changes on cash, cash...
-$7,064K
Canceled cashflow
$262,016K
Purchases of marketable
securities
$261,625K
Purchases of property,
plant and equipment
$21,833K
Purchases of restricted
and other...
$4,100K
Back
Back
Cash Flow
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
source: myfinsight.com